Navigation Links
Barr Receives Approval for Generic Version of Razadyne(R) Tablets
Date:8/28/2008

nd their potential effects on the Company. The statements, analyses, and other information contained herein relating to the proposed merger, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions, are "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future results and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated. Those factors include, without limitation: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire; fluctuations in operating results, including the eff
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
2. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
5. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
6. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
7. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
8. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Underscores Morphotek,s Commitment to the Development of Farletuzumab ... Specialty Development and Manufacturing SolutionsEXTON, Pa. and BASEL, ... of Eisai Corporation of North America, and Lonza ... executed a manufacturing services agreement to support the ...
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... signed an agreement-in-principle to ensure the valorization and the operation ... the Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... 2014Biofuels derived from the oils produced by algae may ... achieve this goal, optimization of cost effective strategies for ... is needed. Sapphire Energy has developed an innovative solution ... cultivation systems, described in Industrial Biotechnology , a ... article is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Genome Atlas (TCGA) Research Network have identified novel ... adenocarcinoma, the most common subtype of lung cancer. ... number of possible therapeutic targets for this disease ... with treatable mutations because many potent cancer drugs ... is jointly funded and managed by the National ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... Hill, CA Bowman Design Group, an integrated marketing and ... marketing, is the first and only company in the ... the German exhibition and events industry association. Third party ... company met or exceeded goals set for nine criteria ...
... DIEGO At the Plenary Session of the American ... AAPS President Tony DeStefano, Ph. D. will present the ... the pharmaceutical sciences: AAPS Ligand Binding Assays ... Alison Joyce, B.S. (lead author); Sheldon Leung, Ph.D.; ...
... When determining the potential effects pesticides could pose ... Protection Agency, National Marine Fisheries Service (NMFS), and ... common scientific approach, says a new report from ... should use a risk assessment approach that addresses ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2AAPS announces 2013 National Biotechnology Conference award winners 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 3
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... is from the C-terminal end of the mouse retinoic acid receptor beta ... to 448 of RAR*. The sequence of PEP-005 is (amino to ... P - S - S - V - E - N - ... P - L - L - Q (The N-terminal cysteine has ...
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... is an automated hybridization system for the ... both the hybridization and post hybridization washing ... single instrument can process up to 12 ... has multi-protocol software, enabling the user to ...
Biology Products: